Pregnancy Outcomes in Late Onset Pompe Disease

Motor and respiratory decline in patients with Late-onset Pompe disease after cessation of enzyme replacement therapy during COVID-19 pandemic

BACKGROUND

Data on interruption of enzyme replacement therapy are scarce in late-onset Pompe disease. Due to the COVID-19 crisis, 8 neuromuscular reference centers in France were obligated to stop the treatment for 31 patients.

METHOD

We collected the motor and respiratory data from our French registry, before COVID-19 and at treatment restart.

RESULTS

In 2.2 months (mean), patients showed a significant deterioration of 37 meters (mean) in the 6-minute walk test and a loss of 210 mL (mean) of forced vital capacity, without ad integrum restoration after 3 months of ERT restart.

CONCLUSION

This national study based on data from the French Pompe registry shows that the interruption of enzyme replacement therapy, even as short as only few months, worsens Pompe patients' motor and respiratory function.

Special Issue "Reproductive Health Concerns for Women"

There are specific health issues concerning the reproductive age of women, including inflammatory disease, fertility, and childbearing [...].